184 related articles for article (PubMed ID: 12437499)
21. Hypolipidemic and antioxidant activity of the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor KY-455 in rabbits and hamsters.
Nakamura S; Kamiya S; Shirahase H; Kanda M; Yoshimi A; Tarumi T; Kurahashi K
Arzneimittelforschung; 2004; 54(2):102-8. PubMed ID: 15038459
[TBL] [Abstract][Full Text] [Related]
22. And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors.
Meuwese MC; Franssen R; Stroes ES; Kastelein JJ
Curr Opin Lipidol; 2006 Aug; 17(4):426-30. PubMed ID: 16832167
[TBL] [Abstract][Full Text] [Related]
23. Role of acyl-coenzyme a: cholesterol acyltransferase activity in the processing of the amyloid precursor protein.
Puglielli L; Ellis BC; Ingano LA; Kovacs DM
J Mol Neurosci; 2004; 24(1):93-6. PubMed ID: 15314256
[TBL] [Abstract][Full Text] [Related]
24. Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits.
Azuma Y; Kawasaki T; Ikemoto K; Obata K; Ohno K; Sajiki N; Yamada T; Yamasaki M; Nobuhara Y
Jpn J Pharmacol; 1998 Nov; 78(3):355-64. PubMed ID: 9869270
[TBL] [Abstract][Full Text] [Related]
25. Acyl-CoA:Cholesterol O-acyltransferase (ACAT) inhibitors. 2. 2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.
Astles PC; Ashton MJ; Bridge AW; Harris NV; Hart TW; Parrott DP; Porter B; Riddell D; Smith C; Williams RJ
J Med Chem; 1996 Mar; 39(7):1423-32. PubMed ID: 8691472
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors.
Shibuya K; Kawamine K; Miura T; Ozaki C; Edano T; Mizuno K; Yoshinaka Y; Tsunenari Y
Bioorg Med Chem; 2018 Aug; 26(14):4001-4013. PubMed ID: 29945757
[TBL] [Abstract][Full Text] [Related]
27. ACAT-selective and nonselective DGAT1 inhibition: adrenocortical effects--a cross-species comparison.
Floettmann JE; Buckett LK; Turnbull AV; Smith T; Hallberg C; Birch A; Lees D; Jones HB
Toxicol Pathol; 2013; 41(7):941-50. PubMed ID: 23427273
[TBL] [Abstract][Full Text] [Related]
28. ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms.
Matsuda K
Med Res Rev; 1994 May; 14(3):271-305. PubMed ID: 8007738
[TBL] [Abstract][Full Text] [Related]
29. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis.
Perrey S; Legendre C; Matsuura A; Guffroy C; Binet J; Ohbayashi S; Tanaka T; Ortuno JC; Matsukura T; Laugel T; Padovani P; Bellamy F; Edgar AD
Atherosclerosis; 2001 Apr; 155(2):359-70. PubMed ID: 11254906
[TBL] [Abstract][Full Text] [Related]
30. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
Chiwata T; Aragane K; Fujinami K; Kojima K; Ishibashi S; Yamada N; Kusunoki J
Br J Pharmacol; 2001 Aug; 133(7):1005-12. PubMed ID: 11487509
[TBL] [Abstract][Full Text] [Related]
31. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
Vaziri ND; Liang KH
Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
[TBL] [Abstract][Full Text] [Related]
32. [Development of new antiatherosclerotic agents--ACAT inhibitors and CETP inhibitors].
Miyazaki A; Horiuchi S
Nihon Rinsho; 1999 Dec; 57(12):2842-7. PubMed ID: 10638223
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents.
Sliskovic DR; White AD
Trends Pharmacol Sci; 1991 May; 12(5):194-9. PubMed ID: 1862535
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure.
Liang K; Vaziri ND
Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E676-81. PubMed ID: 12217884
[TBL] [Abstract][Full Text] [Related]
35. Acyl-Coenzyme A: Cholesterol Acyltransferase Inhibition in Cancer Treatment.
Zabielska J; Sledzinski T; Stelmanska E
Anticancer Res; 2019 Jul; 39(7):3385-3394. PubMed ID: 31262860
[TBL] [Abstract][Full Text] [Related]
36. Novel hydroxyphenylurea dual inhibitor against acyl-CoA: cholesterol acyltransferase (ACAT) and low density lipoprotein (LDL) oxidation as antiatherosclerotic agent.
Nakao K; Kubota H; Yasuhara M; Saito K; Suzuki T; Ohmizu H; Shimizu R
Bioorg Med Chem; 2001 Apr; 9(4):853-61. PubMed ID: 11354668
[TBL] [Abstract][Full Text] [Related]
37. A selective inhibitor of intestinal ACAT, EAB309 suppresses both intestinal and hepatic cholesterol output and stimulates chylomicron removal.
Umeda Y; Hirano T; Kako Y; Kamagata K; Okuyama K; Suzuki K
Life Sci; 1998; 63(13):PL187-95. PubMed ID: 9763214
[TBL] [Abstract][Full Text] [Related]
38. HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits.
Asami Y; Yamagishi I; Murakami S; Araki H; Tsuchida K; Higuchi S
Life Sci; 1998; 62(12):1055-63. PubMed ID: 9519807
[TBL] [Abstract][Full Text] [Related]
39. Cholesterol esterification is not essential for secretion of lipoprotein components by HepG2 cells.
Graham A; Wood JL; Russell LJ
Biochim Biophys Acta; 1996 Jul; 1302(1):46-54. PubMed ID: 8695654
[TBL] [Abstract][Full Text] [Related]
40. Bavachin and isobavachalcone, acyl-coenzyme A: cholesterol acyltransferase inhibitors from Psoralea corylifolia.
Choi JH; Rho MC; Lee SW; Choi JN; Kim K; Song GY; Kim YK
Arch Pharm Res; 2008 Nov; 31(11):1419-23. PubMed ID: 19023538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
